Comunicado de la FDA sobre la seguridad de los medicamentos: Informe actualizado sobre la seguridad del medicamento Revlimid (lenalidomida) para el cáncer y el riesgo de nuevos tipos de neoplasias (nuevos tipos de cáncer)
El 7 de mayo del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público sobre el aumento en el riesgo de segundas neoplasias primarias (nuevos tipos de cáncer) en pacientes con mieloma múltiple de reciente diagnóstico, que tomaron Revlimid (lenalidomida). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news
Natco settles patent litigation with Celgene on cancer drug
Natco and its US partner Allergan have settled a pending litigation with Celgene regarding generic Lenalidomide capsules used for treatment of multiple myeloma. (Source: The Economic Times)
Source: The Economic Times - December 23, 2015 Category: Consumer Health News Source Type: news
Celgene settles U.S. patent litigation for top seller Revlimid
(Reuters) - Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire. (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
BOUDRY, Switzerland & TOKYO--(Healthcare Sales & Marketing Network)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (CELG) today announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally... Biopharmaceuticals, Oncology, RegulatoryCelgene, REVLIMID, lenalidomide, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 21, 2015 Category: Pharmaceuticals Source Type: news
Pomalidomide and Ixazomib Pair Up in Refractory Myeloma (CME/CE)
(MedPage Today) -- Activity observed in patients who progressed on treatment with lenalidomide (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 13, 2015 Category: Primary Care Source Type: news
Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA® (pembrolizumab) Combined With Lenalidomide and Dexamethasone
Dateline City:
KENILWORTH, N.J.
Findings Presented at the 57th American Society of Hematology Annual Meeting Demonstrate Activity of KEYTRUDA Therapy in Previously-Treated Multiple Myeloma Patients When Combined with Lenalidomide and Dexamethasone
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today new study findings investigating the use of KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 th...
Source: Merck.com - Research and Development News - December 7, 2015 Category: Pharmaceuticals Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK ASH Keytruda NYSE:MRK Source Type: news
Addition of bortezomib statistically enhanced the PFS and OS in previously untreated MM
Dr. Brian Durie discussed the randomized phase 3 SWOGG S0777 trial that investigated the addition of bortezomib to lenalidomide and dexamethasone for previously untreated multiple myeloma patients without an intend for immediate autologous stem cell transplant. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 5, 2015 Category: Hematology Source Type: news
Triple Drug Combination Beats Standard Treatment in Myeloma Trial
A SWOG trial shows bortezomib, lenalidomide, and dexamethasone delays recurrence and lengthens life for myeloma patients, indicating a possible new standard of care. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - December 5, 2015 Category: Hematology Source Type: news
Takeda's Ninlaro gets FDA approval to treat multiple myeloma
Takeda Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for Ninlaro (ixazomib) capsules in combination with lenalidomide and dexamethasone to treat patients with multiple myeloma who have received at least one prior… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 23, 2015 Category: Pharmaceuticals Source Type: news
FDA Approves Ninlaro (Ixazomib) for Multiple Myeloma
By Stacy SimonThe US Food and Drug Administration (FDA) has approved the third drug this year for treating multiple myeloma, a type of cancer that starts in plasma cells. Ninlaro (ixazomib) is a targeted therapy drug approved to be given in combination with two other drugs – lenalidomide and dexamethasone. This combination is the first all-oral regimen for treating multiple myeloma. It’s intended for people who have received at least one previous treatment.The FDA based its approval on a clinical trial of 722 people with multiple myeloma that didn’t get better with treatment, or came back after treatment....
Source: American Cancer Society :: News and Features - November 20, 2015 Category: Cancer & Oncology Tags: Multiple Myeloma Source Type: news
Lenalidomide plus rituximab produces durable responses in mantle cell lymphoma patients
The drug combination rituximab plus lenalidomide has been found to be effective and produced long-term responses in patients with mantle cell lymphoma, scientists report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 12, 2015 Category: Science Source Type: news
Lenalidomide plus rituximab produces durable responses in mantle cell lymphoma patients
(H. Lee Moffitt Cancer Center & Research Institute) New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. The results from the multicenter phase 2 study were published in the Nov. 5 issue of The New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 12, 2015 Category: Cancer & Oncology Source Type: news
Lenalidomide + Rituximab: First Line in Mantle Cell LymphomaLenalidomide + Rituximab: First Line in Mantle Cell Lymphoma
The combination lenalidomide and rituximab shows promise as frontline therapy in mantle cell lymphoma, but larger trials and longer follow-up are needed. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 5, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Lenalidomide plus rituximab achieves 87% response rate
First-line combination biologic therapy with lenalidomide plus rituximab produced an 87% overall response rate in stage 3-4 mantle cell lymphoma, in an industry-sponsored, phase II clinical trial reported online Nov. 5 in the New England Journal of Medicine.
Mantle cell lymphoma is generally... (Source: Skin and Allergy News)
Source: Skin and Allergy News - November 4, 2015 Category: Dermatology Source Type: news
New Study Investigates Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
The results of the first clinical trial to investigate carfilzomib (Kyprolis®), pomalidomide (Pomalyst®), and dexamethasone (CPD) in multiple myeloma were published last week in the journal BLOOD . IMF Chairman Dr. Brian Durie, co-author of the study, calls the phase I-II results “remarkably good.” According to Dr. Durie, the well-tolerated regime produces remissions lasting approximately one year, and overall survival of close to two years, in the very-poor-risk setting of double refractory disease in which patients are resistant to both lenalidomide (Revlimid®) and bortezomib (Velcade®). (Source: ...
Source: International Myeloma Foundation - September 25, 2015 Category: Hematology Source Type: news
